Newtyn Management 13F annual report
Newtyn Management is an investment fund managing more than $400 billion ran by Eugene Dozortsev. There are currently 41 companies in Mr. Dozortsev’s portfolio. The largest investments include Cannae Inc and IAC Inc, together worth $100 billion.
$400 billion Assets Under Management (AUM)
As of 7th November 2023, Newtyn Management’s top holding is 2,868,411 shares of Cannae Inc currently worth over $53.5 billion and making up 13.4% of the portfolio value.
Relative to the number of outstanding shares of Cannae Inc, Newtyn Management owns more than approximately 0.1% of the company.
In addition, the fund holds 930,000 shares of IAC Inc worth $46.9 billion, whose value fell approximately 0.1% in the past six months.
The third-largest holding is Par Technology worth $37.9 billion and the next is Merrimack Pharmaceuticals In worth $23.1 billion, with 1,873,694 shares owned.
Currently, Newtyn Management's portfolio is worth at least $400 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Newtyn Management
The Newtyn Management office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Eugene Dozortsev serves as the Managing Member at Newtyn Management.
Recent trades
In the most recent 13F filing, Newtyn Management revealed that it had opened a new position in
G-III Apparel and bought 818,816 shares worth $20.4 billion.
This means they effectively own approximately 0.1% of the company.
G-III Apparel makes up
52.3%
of the fund's Consumer Discretionary sector allocation and has grown its share price by 28.7% in the past year.
The investment fund also strengthened its position in Cannae Inc by buying
1,468,411 additional shares.
This makes their stake in Cannae Inc total 2,868,411 shares worth $53.5 billion.
Cannae Inc dropped 28.9% in the past year.
On the other hand, there are companies that Newtyn Management is getting rid of from its portfolio.
Newtyn Management closed its position in Blucora Inc on 14th November 2023.
It sold the previously owned 1,748,389 shares for $32.3 million.
Eugene Dozortsev also disclosed a decreased stake in Par Technology by approximately 0.1%.
This leaves the value of the investment at $37.9 billion and 982,527 shares.
One of the average hedge funds
The two most similar investment funds to Newtyn Management are Orion Resource Partners (usa) L.P. and Evr Research L.P.. They manage $400 billion and $400 billion respectively.
Eugene Dozortsev investment strategy
Newtyn Management’s portfolio is diversified across 8 sectors.
Currently, their heaviest sector is Technology — making up 21.2% of
the total portfolio value.
The fund focuses on investments in the United States as
53.7% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
12% of the total holdings value.
On the other hand, large-cap stocks make up only 2.4% of the portfolio.
The average market cap of the portfolio companies is close to $1.89 billion.
The complete list of Newtyn Management trades based on 13F SEC filings
These positions were updated on November 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Cannae Holdings Inc |
104.89%
2,868,411
|
$53,467,181,000 | 13.38% |
| IAC Inc |
177.61%
930,000
|
$46,862,700,000 | 11.73% |
| Par Technology Corp. |
3.49%
982,527
|
$37,866,591,000 | 9.48% |
| Merrimack Pharmaceuticals In |
6.58%
1,873,694
|
$23,102,647,000 | 5.78% |
| Ardagh Metal Packaging S A |
19.31%
7,188,138
|
$22,498,872,000 | 5.63% |
| G-III Apparel Group Ltd. |
Opened
818,816
|
$20,404,895,000 | 5.11% |
| Spectrum Brands Hldgs Inc Ne |
No change
249,937
|
$19,582,564,000 | 4.90% |
| Bristow Group Inc |
73.77%
692,896
|
$19,518,880,000 | 4.88% |
| Theravance Biopharma Inc |
9.63%
1,841,560
|
$15,892,663,000 | 3.98% |
| City Office REIT Inc |
190.41%
3,180,000
|
$13,515,000,000 | 3.38% |
| 2seventy Bio Inc |
128.43%
3,076,490
|
$12,059,841,000 | 3.02% |
| Garrett Motion Inc |
Opened
1,335,572
|
$10,524,307,000 | 2.63% |
| MBIA Inc. |
9.97%
1,425,000
|
$10,274,250,000 | 2.57% |
| Galapagos NV |
61.76%
275,000
|
$9,501,250,000 | 2.38% |
| Bv Finl Inc |
Opened
879,341
|
$8,863,757,000 | 2.22% |
| Cyteir Therapeutics Inc |
312.45%
2,500,444
|
$7,101,261,000 | 1.78% |
| NI Holdings Inc |
6.82%
470,000
|
$6,048,900,000 | 1.51% |
| Tillys Inc |
6.81%
662,247
|
$5,377,446,000 | 1.35% |
| PFSWEB Inc |
37.08%
711,953
|
$5,296,930,000 | 1.33% |
| Phathom Pharmaceuticals Inc |
95.49%
500,000
|
$5,185,000,000 | 1.30% |
| Forum Energy Technologies In |
Opened
183,300
|
$4,402,866,000 | 1.10% |
| PG&E Corp. |
67.99%
268,921
|
$4,337,696,000 | 1.09% |
| Star Hldgs |
Opened
326,472
|
$4,087,430,000 | 1.02% |
| Algoma Stl Group Inc |
60.61%
590,899
|
$4,018,113,000 | 1.01% |
| 89bio Inc |
35.32%
200,500
|
$3,095,720,000 | 0.77% |
| AvroBio Inc |
Opened
2,000,000
|
$3,080,000,000 | 0.77% |
| Wave Life Sciences Ltd. |
26.38%
510,000
|
$2,932,500,000 | 0.73% |
| Kodiak Sciences Inc |
121.89%
1,608,694
|
$2,895,649,000 | 0.72% |
| Destination XL Group Inc |
33.33%
600,000
|
$2,688,000,000 | 0.67% |
| Orion Office REIT Inc. |
82.80%
474,721
|
$2,473,296,000 | 0.62% |
| Olema Pharmaceuticals, Inc. |
70.00%
150,000
|
$1,852,500,000 | 0.46% |
| Apartment Invt & Mgmt Co |
Opened
231,865
|
$1,576,682,000 | 0.39% |
| Adverum Biotechnologies Inc |
0.97%
1,025,000
|
$1,537,500,000 | 0.38% |
| Sensei Biotherapeutics Inc |
333.73%
1,800,000
|
$1,350,180,000 | 0.34% |
| Graphite Bio Inc |
Opened
542,637
|
$1,345,740,000 | 0.34% |
| Atea Pharmaceuticals, Inc. |
Opened
400,000
|
$1,200,000,000 | 0.30% |
| Bolt Biotherapeutics Inc |
36.32%
1,020,000
|
$1,060,800,000 | 0.27% |
| Mersana Therapeutics Inc |
Opened
700,000
|
$889,000,000 | 0.22% |
| Aligos Therapeutics, Inc. |
4.37%
920,000
|
$687,240,000 | 0.17% |
| ARCA biopharma Inc |
Opened
300,000
|
$603,000,000 | 0.15% |
| Black Diamond Therapeutics I |
60.58%
205,000
|
$588,350,000 | 0.15% |
| Blucora Inc |
Closed
1,748,389
|
$32,275,000 | |
| Garrett Motion Inc |
Closed
2,315,058
|
$19,030,000 | |
| Adient plc |
Closed
421,293
|
$12,483,000 | |
| Epizyme Inc |
Closed
7,569,995
|
$11,128,000 | |
| Lamb Weston Holdings Inc |
Closed
150,000
|
$10,719,000 | |
| Amplify Energy Corp. |
Closed
1,075,000
|
$7,031,000 | |
| Liquidia Corp |
Closed
1,568,627
|
$6,839,000 | |
| Virtus Invt Partners Inc |
Closed
39,500
|
$6,755,000 | |
| Customers Bancorp Inc |
Closed
150,000
|
$5,085,000 | |
| Uniqure Nv |
Closed
272,091
|
$5,072,000 | |
| Nexpoint Diversified Rel Et |
Closed
250,000
|
$4,123,000 | |
| Stitch Fix Inc |
Closed
825,000
|
$4,076,000 | |
| Schnitzer Steel Industries Inc. |
Closed
381,998
|
$3,961,000 | |
| Rlj Lodging Tr |
Closed
125,607
|
$3,257,000 | |
| Danimer Scientific, Inc. |
Closed
625,000
|
$2,850,000 | |
| Intevac, Inc. |
Closed
504,035
|
$2,440,000 | |
| Compx International, Inc. |
Closed
100,000
|
$2,319,000 | |
| TCR2 Therapeutics Inc. |
Closed
692,799
|
$2,009,000 | |
| CytomX Therapeutics Inc |
Closed
1,073,400
|
$1,964,000 | |
| Pyxis Oncology Inc |
Closed
800,000
|
$1,904,000 | |
| Collegium Pharmaceutical Inc |
Closed
105,000
|
$1,861,000 | |
| Alerislife Inc |
Closed
1,500,000
|
$1,800,000 | |
| Atai Life Sciences Nv |
Closed
470,000
|
$1,711,000 | |
| Latch Inc |
Closed
1,500,000
|
$1,710,000 | |
| Global Business Travel Group |
Closed
245,208
|
$1,547,000 | |
| Passage Bio Inc |
Closed
620,000
|
$1,463,000 | |
| Sema4 Holdings Corp |
Closed
1,145,000
|
$1,443,000 | |
| Adagio Therapeutics Inc |
Closed
400,875
|
$1,315,000 | |
| Decibel Therapeutics Inc |
Closed
310,000
|
$1,305,000 | |
| Iovance Biotherapeutics Inc |
Closed
105,000
|
$1,159,000 | |
| Alector, Inc. |
Closed
105,000
|
$1,067,000 | |
| Eargo, Inc. |
Closed
1,312,066
|
$987,000 | |
| Alpha Metallurgical Resour I |
Closed
6,319
|
$816,000 | |
| Tscan Therapeutics Inc |
Closed
248,611
|
$782,000 | |
| Qudian Inc |
Closed
690,290
|
$759,000 | |
| Nuvation Bio Inc |
Closed
210,000
|
$680,000 | |
| Oric Pharmaceuticals, Inc. |
Closed
150,000
|
$672,000 | |
| Rafael Holdings Inc |
Closed
300,000
|
$561,000 | |
| Sio Gene Therapies Inc |
Closed
1,415,859
|
$510,000 | |
| Kronos Bio, Inc. |
Closed
126,623
|
$461,000 | |
| Doma Holdings Inc |
Closed
300,000
|
$309,000 | |
| Talis Biomedical Corp |
Closed
284,726
|
$231,000 | |
| Amryt Pharma plc |
Closed
29,656
|
$207,000 | |
| BioAtla, Inc. |
Closed
65,332
|
$186,000 | |
| EchoStar Corp |
Closed
7,862
|
$152,000 | |
| Reneo Pharmaceuticals Inc |
Closed
20,983
|
$56,000 | |
| No transactions found | |||
| Showing first 500 out of 87 holdings | |||
Hedge funds similar to Newtyn Management
- Onyx Bridge Wealth
- Icon Advisers Inc/co
- Mcnamara Services
- Carolinas Wealth Consulting
- Greystone
- Evr Research L.P.
- Orion Resource Partners (usa) L.P.
- Thunderbird Partners LL.P.
- Sphera Funds Management Ltd
- Osher Van De Voorde Investment Management
- Vector Capital Management, L.P.
- Crane Advisory
- Sjs Investment Consulting
- Chicago Trust Co Na